HLB Pep Co., Ltd.

196300· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences

₩4,245+2.04%

2026-08-04

Financials

Valuation Metrics

HLB Pep Co., Ltd.'s Market Cap is ₩398B. At end of 2025 it was ₩671B. Ranked #1887 of 2,436 in KR market (top 77%), #1171 of 1,649 on KOSDAQ (top 71%), #204 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 87%) by Market Cap.

Investment Metrics(as of 2026-08-04)

Metric	Value	Rank
Size
Market Cap	39.80B KRW	KR#1,887/2,436 Sec#204/234
Revenue	5.52B KRW	KR#2,340/2,436 Sec#195/234
Net Income	-2.07B KRW	KR—/2,436 Sec—/234
Total Assets	50.60B KRW	KR#2,187/2,436 Sec#197/234
Net Assets	22.98B KRW	KR#2,242/2,436 Sec#208/234
Employees	83	KR#1,770/2,436 Sec#144/234
Value
P/B	1.73x	KR#1,885/2,436 Sec#137/234
P/S	7.22x	KR#2,219/2,436 Sec#152/234
FCF Yield	-26.94%	KR—/2,436 Sec—/234
Profitability
ROE	-9.02%	KR#1,880/2,436 Sec#145/234
ROA	-4.10%	KR#1,845/2,436 Sec#136/234
Op. Margin	-138.98%	KR#2,332/2,436 Sec#183/234
Revenue Growth	50.86%	KR#295/2,436 Sec#31/234
Financial Health
Debt Ratio	220.21%	KR#1,841/2,436 Sec#201/234
Total Debt	16.47B KRW	KR#1,432/2,436 Sec#122/234
FCF	-10.72B KRW	KR#1,732/2,436 Sec#151/234
Cash	1.44B KRW	KR#2,300/2,436 Sec#221/234
Current Ratio	1.21x	KR#1,566/2,436 Sec#163/234
Performance
1Y Return	-45.30%	KR#1,969/2,436 Sec#177/234
1M Return	-3.96%	KR#1,298/2,436 Sec#132/234
From 52W High	-57.51%	KR#1,590/2,436 Sec#135/234
1Y MDD	-60.48%	KR#1,437/2,436 Sec#116/234
Trading
Volume	5,765 shares	KR#2,240/2,436 Sec#221/234
Foreign Own.	2.06%	KR—/2,436 Sec—/234
Per Share
EPS	-223 KRW	KR—/2,436 Sec—/234
BPS	2,472 KRW	KR#1,914/2,436 Sec#153/234

Company Info

CEO 심경재 (단독 대표)

Employees 83

Founded 2000

HQ 광주광역시 북구, KR

Website www.anygen.com

동사는 2000년 펩타이드 바이오소재 및 글로벌 혁신 신약 개발 회사로 설립됨. 의약품, 원료의약품, 의약부외품 제조·판매 및 생명공학 관련 연구개발업을 영위하며, 의약용 펩타이드 소재 40.36%, 연구용 펩타이드 소재 54.93%의 매출 비중을 보임. APsoluT 플랫폼 기술로 유방암, 위암, 대장암 신약 후보 발굴 및 네트워킹을 통한 연구개발 진행하고 있음. HLB펩는 2000년에 설립되었으며 광주광역시 북구에 본사를 두고 있습니다.